Navigation Links
Cepheid Extends Rapid Molecular Diagnostics' Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Date:4/11/2011

turing problems; uncertainties in the regulatory review process for new products; regulatory developments and practices regarding testing; customer and market acceptance of the product; the failure of the product to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the product; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

References

(1) - Louie T, Miller M, Mullane K, et al.  Fidaxomicin versus Vancomycin for Clostridium difficile Infection.  N Engl J Med 2011 ; 364 :422-31CONTACTS:For Media Inquiries:For Cepheid Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

408-400-8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

408-400-8329

investor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
2. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
3. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
4. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
5. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
6. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
7. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
8. Cepheid Reports 2009 Third Quarter Results
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
11. Cepheid to Webcast Upcoming Financial Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Hill-Rom,s recent ... $2 billion in cash and stock means the ... market, according to Kalorama Information. The healthcare market ... the medical device and advanced wound care markets, ... beds, patient lifting devices, and other healthcare equipment. ...
(Date:7/7/2015)... , July 7, 2015  Shareholder rights law ... a federal securities fraud class action complaint was ... Southern District of California.  The complaint alleges that ... CLDN ) violated the Securities Exchange Act of ... 2015, by making materially false and misleading statements ...
(Date:7/7/2015)... 7, 2015 According to ... Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, ... Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, ... by MarketsandMarkets, this report studies the global Nuclear ... to 2020. This market is expected to reach ...
Breaking Medicine Technology:Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 2Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed Class Action 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 2Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 4
(Date:7/7/2015)... ... July 07, 2015 , ... Celestix Networks, the leading provider ... VA Series virtual appliances. These virtual platforms expand the existing physical appliances ... proven to simplify the on-premises deployment of unified remote access and single sign-on ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
(Date:7/7/2015)... ... 2015 , ... The Immune Deficiency Foundation (IDF) launched a ... its IDF ePHR, an electronic personal health record powered by Get Real Health’s ... their health information, including symptoms, diagnoses, medications, infusions and other critical health data. ...
(Date:7/7/2015)... ... July 07, 2015 , ... On ... was the site of the National Baptist Convention 110th Annual Session of the ... and promoting the collaboration of churches and their congregations, medical professionals and health-related ...
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri ... whitening treatments. A professional teeth whitening is one of the fastest, easiest ways to ... as they can decrease smile satisfaction and confidence. With the right teeth whitening treatment, ...
Breaking Medicine News(10 mins):Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 2Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 3Health News:Celestix Now Offers Virtual Editions of Its Unified Remote Access and SSO Platforms to Enable Easy Deployment in Virtualized Environments 4Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3
... dead, without government ... Americans, DES MOINES, Iowa, Dec. 10 Print ads ... Nurses,Association (CNA)/National Nurses Organizing Committee (NNOC) is running,the ads as ... for all Americans through a Medicare-based system., The ad ...
... to Head Department, BANNOCKBURN, Ill., Dec. ... a contract research organization serving,pharmaceutical and biotechnology ... Wozniak, Ph.D., as Director, Statistical Programming. Dr.,Wozniak ... ACRS facilitates successful clinical trials by ...
... the Medicare End Stage Renal Disease Program Recommends,Policy ... Awareness, WASHINGTON, Dec. 10 The Association ... today,released a consensus report addressing proposed changes to ... are currently being considered by,the U.S. Congress., ...
... challenges traditional assessment of risk , , MONDAY, Dec. 10 ... at low risk for heart disease still face potential ... a new study suggests. , "Previous studies have demonstrated ... other populations," said study lead author Dr. Susan G. ...
... higher than dentists do, according to a new study. Teeth ... attractive face, the study also found, and people younger than ... published in this months Journal of the American Dental Association ... smiles on a 100-point satisfaction scale. Later, the patients regular ...
... and Nexium , , MONDAY, Dec. 10 (HealthDay News) ... heartburn drugs Prilosec and Nexium found no evidence of ... announcement followed a three-month safety review after reports of ... detailed data from both studies, plus another 14 studies, ...
Cached Medicine News:Health News:RNs Sponsor Hard-Hitting Health Care Ads in Top 10 Iowa Papers 2Health News:Advanced Clinical Research Services Enhances Biostatistics Offering 2Health News:Kidney Patients' Health Is Jeopardized by Proposed Medicare Changes 2Health News:Kidney Patients' Health Is Jeopardized by Proposed Medicare Changes 3Health News:Kidney Patients' Health Is Jeopardized by Proposed Medicare Changes 4Health News:Coronary Artery Calcium May Raise Women's Heart Risk 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 3
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: